- Home
- MYNZ vs KLTO Comparison
MYNZ vs KLTO Comparison
Compare MYNZ & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYNZ
- KLTO
- Stock Information
- Founded
- MYNZ 2021
- KLTO 2019
- Country
- MYNZ Germany
- KLTO United States
- Employees
- MYNZ N/A
- KLTO N/A
- Industry
- MYNZ Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- MYNZ Health Care
- KLTO
- Exchange
- MYNZ Nasdaq
- KLTO NYSE
- Market Cap
- MYNZ 5.5M
- KLTO 5.9M
- IPO Year
- MYNZ 2021
- KLTO N/A
- Fundamental
- Price
- MYNZ $1.44
- KLTO $1.14
- Analyst Decision
- MYNZ Buy
- KLTO
- Analyst Count
- MYNZ 2
- KLTO 0
- Target Price
- MYNZ $14.00
- KLTO N/A
- AVG Volume (30 Days)
- MYNZ 117.3K
- KLTO 92.0M
- Earning Date
- MYNZ 07-15-2025
- KLTO 08-15-2025
- Dividend Yield
- MYNZ N/A
- KLTO N/A
- EPS Growth
- MYNZ N/A
- KLTO N/A
- EPS
- MYNZ N/A
- KLTO N/A
- Revenue
- MYNZ $893,991.00
- KLTO N/A
- Revenue This Year
- MYNZ $26.06
- KLTO N/A
- Revenue Next Year
- MYNZ $4.97
- KLTO N/A
- P/E Ratio
- MYNZ N/A
- KLTO N/A
- Revenue Growth
- MYNZ N/A
- KLTO N/A
- 52 Week Low
- MYNZ $1.34
- KLTO $0.11
- 52 Week High
- MYNZ $22.40
- KLTO $3.91
- Technical
- Relative Strength Index (RSI)
- MYNZ 26.61
- KLTO N/A
- Support Level
- MYNZ $1.35
- KLTO N/A
- Resistance Level
- MYNZ $1.46
- KLTO N/A
- Average True Range (ATR)
- MYNZ 0.12
- KLTO 0.00
- MACD
- MYNZ 0.02
- KLTO 0.00
- Stochastic Oscillator
- MYNZ 9.27
- KLTO 0.00
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.